U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C3H7NO2
Molecular Weight 89.0932
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Urethane

SMILES

CCOC(N)=O

InChI

InChIKey=JOYRKODLDBILNP-UHFFFAOYSA-N
InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)

HIDE SMILES / InChI

Molecular Formula C3H7NO2
Molecular Weight 89.0932
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/28818685 | https://www.ncbi.nlm.nih.gov/pubmed/18921082 https://www.ncbi.nlm.nih.gov/pubmed/2188890

Urethane (Ethyl carbamate) is is an ethyl ester of carbamic acid, that has been found in many fermented food products and alcoholic beverages such as cheese, bread, yogurt, wine, whiskey, soya sauce etc. An in vitro study indicated that Urethane has a potential to inhibit the growth of bacteria, plant tissue, and rat carcinoma. Urethane has been used for many years as an antineoplastic agent for medical purposes but this application ended after it was discovered to be carcinogenic in 1943. Urethane can produce long-lasting anesthesia without affecting blood gases or blood pressure, it has been used in acute studies. In earlier studies, Urethane was also used as a co-solvent for water-insoluble analgesic and sedative drugs in Japan. By US FDA regulations, ethyl carbamate has been withdrawn from pharmaceutical use. However, small quantities of ethyl carbamate are also used in laboratories as an anesthetic for animals.

Originator

Sources: Berichte der Deutschen Chemischen Gesellschaft 23, 1856-69. From: J. Chem. Soc., Abstr. 58, 1082-3 1890.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
URETHANE

Approved Use

Unknown
Primary
URETHANE

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
0.5 g 3 times / day multiple, oral
Studied dose
Dose: 0.5 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.5 g, 3 times / day
Sources:
unhealthy, 2 year
Health Status: unhealthy
Age Group: 2 year
Sex: F
Sources:
Other AEs: Vomiting, White blood cell increased...
Other AEs:
Vomiting (1 patient)
White blood cell increased (grade 5, 1 patient)
Hemorrhage (grade 5, 1 patient)
Sources:
10 % multiple, topical
Dose: 10 %
Route: topical
Route: multiple
Dose: 10 %
Sources:
unhealthy, 21 years
Health Status: unhealthy
Age Group: 21 years
Sex: M
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (1 patient)
Vomiting (1 patient)
Leukopenia (grade 5, 1 patient)
Hemorrhage (grade 5, 1 patient)
Renal disorder NOS (grade 5, 1 patient)
Liver injury (grade 5, 1 patient)
Sources:
6 g 1 times / day multiple, oral
Studied dose
Dose: 6 g, 1 times / day
Route: oral
Route: multiple
Dose: 6 g, 1 times / day
Sources:
unhealthy, 51-76 years
Health Status: unhealthy
Age Group: 51-76 years
Sex: M+F
Sources:
Other AEs: Anorexia, Leukopenia...
Other AEs:
Anorexia (4 patients)
Leukopenia (1 patient)
Weight loss (severe, 1 patient)
Neutrophilia (1 patient)
Nausea (1 patient)
Vomiting (1 patient)
Sources:
10 g multiple, intravenous
Dose: 10 g
Route: intravenous
Route: multiple
Dose: 10 g
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Drowsiness...
Other AEs:
Drowsiness (slight)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting 1 patient
0.5 g 3 times / day multiple, oral
Studied dose
Dose: 0.5 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.5 g, 3 times / day
Sources:
unhealthy, 2 year
Health Status: unhealthy
Age Group: 2 year
Sex: F
Sources:
Hemorrhage grade 5, 1 patient
0.5 g 3 times / day multiple, oral
Studied dose
Dose: 0.5 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.5 g, 3 times / day
Sources:
unhealthy, 2 year
Health Status: unhealthy
Age Group: 2 year
Sex: F
Sources:
White blood cell increased grade 5, 1 patient
0.5 g 3 times / day multiple, oral
Studied dose
Dose: 0.5 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.5 g, 3 times / day
Sources:
unhealthy, 2 year
Health Status: unhealthy
Age Group: 2 year
Sex: F
Sources:
Nausea 1 patient
10 % multiple, topical
Dose: 10 %
Route: topical
Route: multiple
Dose: 10 %
Sources:
unhealthy, 21 years
Health Status: unhealthy
Age Group: 21 years
Sex: M
Sources:
Vomiting 1 patient
10 % multiple, topical
Dose: 10 %
Route: topical
Route: multiple
Dose: 10 %
Sources:
unhealthy, 21 years
Health Status: unhealthy
Age Group: 21 years
Sex: M
Sources:
Hemorrhage grade 5, 1 patient
10 % multiple, topical
Dose: 10 %
Route: topical
Route: multiple
Dose: 10 %
Sources:
unhealthy, 21 years
Health Status: unhealthy
Age Group: 21 years
Sex: M
Sources:
Leukopenia grade 5, 1 patient
10 % multiple, topical
Dose: 10 %
Route: topical
Route: multiple
Dose: 10 %
Sources:
unhealthy, 21 years
Health Status: unhealthy
Age Group: 21 years
Sex: M
Sources:
Liver injury grade 5, 1 patient
10 % multiple, topical
Dose: 10 %
Route: topical
Route: multiple
Dose: 10 %
Sources:
unhealthy, 21 years
Health Status: unhealthy
Age Group: 21 years
Sex: M
Sources:
Renal disorder NOS grade 5, 1 patient
10 % multiple, topical
Dose: 10 %
Route: topical
Route: multiple
Dose: 10 %
Sources:
unhealthy, 21 years
Health Status: unhealthy
Age Group: 21 years
Sex: M
Sources:
Leukopenia 1 patient
6 g 1 times / day multiple, oral
Studied dose
Dose: 6 g, 1 times / day
Route: oral
Route: multiple
Dose: 6 g, 1 times / day
Sources:
unhealthy, 51-76 years
Health Status: unhealthy
Age Group: 51-76 years
Sex: M+F
Sources:
Nausea 1 patient
6 g 1 times / day multiple, oral
Studied dose
Dose: 6 g, 1 times / day
Route: oral
Route: multiple
Dose: 6 g, 1 times / day
Sources:
unhealthy, 51-76 years
Health Status: unhealthy
Age Group: 51-76 years
Sex: M+F
Sources:
Neutrophilia 1 patient
6 g 1 times / day multiple, oral
Studied dose
Dose: 6 g, 1 times / day
Route: oral
Route: multiple
Dose: 6 g, 1 times / day
Sources:
unhealthy, 51-76 years
Health Status: unhealthy
Age Group: 51-76 years
Sex: M+F
Sources:
Vomiting 1 patient
6 g 1 times / day multiple, oral
Studied dose
Dose: 6 g, 1 times / day
Route: oral
Route: multiple
Dose: 6 g, 1 times / day
Sources:
unhealthy, 51-76 years
Health Status: unhealthy
Age Group: 51-76 years
Sex: M+F
Sources:
Anorexia 4 patients
6 g 1 times / day multiple, oral
Studied dose
Dose: 6 g, 1 times / day
Route: oral
Route: multiple
Dose: 6 g, 1 times / day
Sources:
unhealthy, 51-76 years
Health Status: unhealthy
Age Group: 51-76 years
Sex: M+F
Sources:
Weight loss severe, 1 patient
6 g 1 times / day multiple, oral
Studied dose
Dose: 6 g, 1 times / day
Route: oral
Route: multiple
Dose: 6 g, 1 times / day
Sources:
unhealthy, 51-76 years
Health Status: unhealthy
Age Group: 51-76 years
Sex: M+F
Sources:
Drowsiness slight
10 g multiple, intravenous
Dose: 10 g
Route: intravenous
Route: multiple
Dose: 10 g
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Enzyme-induced biodegradation of polycarbonate polyurethanes: dependence on hard-segment concentration.
2001-09-15
Excitatory stimulation of neurons in the arcuate nucleus inhibits gastric acid secretion via vagal pathways in anesthetized rats.
2001-09-14
Discrete regions in the laterodorsal tegmental area of the rat regulating the urinary bladder and external urethral sphincter.
2001-09-07
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
2001-09-06
GDNF improves cerebellar Purkinje neuron function in aged F344 rats.
2001-09-01
The release of spinal prostaglandin E2 and the effect of nitric oxide synthetase inhibition during strychnine-induced allodynia.
2001-09
Abrogation of alpha-adrenergic vasoactivity in chronically inflamed rat knee joints.
2001-09
The application of magnetic resonance microimaging to the visible light curing of dental resins. 3. Stray-field nuclear magnetic resonance imaging (STRAFI).
2001-09
In vitro comparison of cuspal fracture resistances of posterior teeth restored with various adhesive restorations.
2001-08-18
Indomethacin reduces lung adenoma number in A/J mice.
2001-08-11
Extracellular signal-regulated kinases 1 and 2 phosphorylated neurons in the tele- and diencephalon of rat after visceral pain stimulation: an immunocytochemical study.
2001-08-10
Shear bond strength of denture reline polymers to denture base polymers.
2001-08-04
Clinical wear performance of eight experimental dental composites over three years determined by two measuring methods.
2001-08
Capillary zone electrophoresis for the characterization of latex particles.
2001-08
Anesthetic induction agents, sympathetic nerve activity and baroreflex sensitivity: a study in rabbits comparing thiopental, propofol and etomidate.
2001-08
Cardiovascular effects of the methanol and dichloromethanol extracts from Mentha suaveolens Ehrh.
2001-08
Involvement of a urethane-sensitive system in timing the onset of gastrulation in Xenopus laevis embryos.
2001-08
Effects of anesthesia on cystometry and leak point pressure of the female rat.
2001-07-27
Macroporous copolymer matrix. IV. Expanded bed adsorption application.
2001-07-13
Anesthesia alters NO-mediated functional hyperemia.
2001-07-13
Fine chromosomal localization of the mouse Par2 gene that confers resistance against urethane-induction of pulmonary adenomas.
2001-07-05
Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist.
2001-07-05
Preferential acetazolamide-induced vasodilation based on vessel size and organ: confirmation of peripheral vasodilation with use of colored microspheres.
2001-07
Occupational hypersensitivity pneumonitis due to isocyanates: mechanisms of action and case reports in Japan.
2001-07
Effect of nitric oxide synthase inhibition on fos expression in the hypothalamus of female rats following central oxytocin and systemic urethane administration.
2001-07
Flexural behaviour of post-cured composites at oral-simulating temperatures.
2001-07
Denture base polymer Alldent Sinomer: mechanical properties, water sorption and release of residual compounds.
2001-07
Use of a simplified method of optical recording to identify foci of maximal neuron activity in the somatosensory cortex of white rats.
2001-06-05
Delayed-type hypersensitivity and humoral immunity modulation by dietary lipids in a murine model of pulmonary tumorigenesis induced by urethan.
2001-06
Azo-containing urethane analogues for colonic drug delivery: synthesis, characterization and in-vitro evaluation.
2001-06
Copper(II) catalysis in cyanide conversion into ethyl carbamate in spirits and relevant reactions.
2001-06
Topical bicuculline to the rat spinal cord induces highly localized allodynia that is mediated by spinal prostaglandins.
2001-06
Sympathetic nerve and cardiovascular responses to chemical activation of the midbrain defense region.
2001-06
Muscarinic dependence of nucleus basalis induced conditioned receptive field plasticity.
2001-05-25
[Liver angiosarcoma in humans: epidemiologic considerations].
2001-05-23
2-Chloroacetaldehyde induces epsilondA DNA adducts in DNA of Raji cells as demonstrated by an improved HPLC-fluorimetry method.
2001-05
An in vitro wear study of posterior denture tooth materials on human enamel.
2001-05
Optimization of an exogenous metabolic activation system for FETAX. II. Preliminary evaluation.
2001-05
Adrenomedullin acts in the rat paraventricular nucleus to decrease blood pressure.
2001-05
The role of alpha(1)-adrenoceptors and 5-HT(1A) receptors in the control of the micturition reflex in male anaesthetized rats.
2001-05
Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development.
2001-05
Two unusual glycerophospholipids from a filamentous fungus, Absidia corymbifera.
2001-04-30
Stimulatory effects of centrally injected kappa-opioid receptor agonists on gastric acid secretion in urethane-anesthetized rats.
2001-04-27
A novel traceless resin-bound guanidinylating reagent for secondary amines to prepare N,N-disubstituted guanidines.
2001-04-19
Monoclonal antibody to rat galanin: production, characterization, and in vivo immunoneutralization activity.
2001-04
The effects of moisture on the dielectric relaxation of urethane dimethacrylate polymer and composites.
2001-04
Modulation of diaspirin crosslinked hemoglobin induced systemic and regional hemodynamic response by ethanol in normal rats.
2001-02-09
Differences in parasympathetic vasodilator and salivary responses in the cat submandibular gland between lingual and chorda-lingual nerve stimulation.
2001-02
A role of proton transfer in peroxidase-catalyzed process elucidated by substrates docking calculations.
2001
[A plastic property in the change of rat muscle potentials clarified in the presence of neostigmine: a conjecture on the recycling process of ACh].
2001
Patents

Sample Use Guides

In the 1940s, ethyl carbamate was used in man at doses of 1 g/person/day
Route of Administration: Oral
HepG2 cells were cultured in DMEM medium containing 10% fetal bovine serum and 1% mixture of penicillin (100 IU/ml) and streptomycin (100g/ml) at 37 °C in the presence of 5% CO2. Cells at 80% confluent were treated with 100 mM (dissolved in DMEM medium) for different times and cell viability and mortality were timely examined. Cells without EC (Urethane) treatment were grown at the same time as control. For metabolomics and transcriptomic analyses, cells were collected at 4 h and 12 h after treatment, respectively, digested with trypsin and centrifuged in 2 mL Eppendorf tubes at 1000 rpm for 5 min in 4 °C. The cell pellets were washed with ice-cold PBS solution twice, frozen immediately in liquid nitrogen and stored at −80 °C until analysis.
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:16:41 GMT 2025
Edited
by admin
on Wed Apr 02 09:16:41 GMT 2025
Record UNII
3IN71E75Z5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Urethane
HSDB   INN   WHO-DD  
INN  
Official Name English
URETHAN
MI  
Preferred Name English
ETHYL-CARBAMATE
Systematic Name English
Urethane [WHO-DD]
Common Name English
CARBAMIC ACID, ETHYL ESTER
Common Name English
URETHAN [MI]
Common Name English
NSC-746
Code English
O-ETHYLURETHANE
Common Name English
ETHYL CARBAMATE
Systematic Name English
PRACARBAMINE
Common Name English
ETHYL AMINOFORMATE
Systematic Name English
urethane [INN]
Common Name English
URETHANE [HSDB]
Common Name English
LEUCETHANE
Common Name English
ETHYL CARBAMATE [IARC]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C45176
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
CFR 21 CFR 216.24
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
Code System Code Type Description
DAILYMED
3IN71E75Z5
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
SMS_ID
100000076664
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
MERCK INDEX
m11329
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
Ethyl carbamate
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
PUBCHEM
5641
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
EVMPD
SUB11388MIG
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-123-1
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
CAS
51-79-6
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
MESH
D014520
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
ChEMBL
CHEMBL462547
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
EPA CompTox
DTXSID9021427
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
HSDB
2555
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
CHEBI
17967
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
NCI_THESAURUS
C920
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
DRUG BANK
DB04827
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
FDA UNII
3IN71E75Z5
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
INN
1329
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
NSC
746
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY
RXCUI
1420982
Created by admin on Wed Apr 02 09:16:41 GMT 2025 , Edited by admin on Wed Apr 02 09:16:41 GMT 2025
PRIMARY RxNorm
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY